An analysis of CMS data between 2009 and 2011 showed higher costs per beneficiary were a result of medication choice, with more expensive chemotherapy drugs used in outpatient settings. It also showed that chemotherapy days were between 9 and 12 percent higher in outpatient care settings.
Overall discrepancies in cancer treatment costs may be a result of differences in updates to the Medicare Physician Fee Schedule and the Outpatient Prospective Payment system, according to the report.
More Articles on Quality:
Study: Futile Care is Frequent, Costly
Henry Ford Health System: Patient Safety Organizations Provide Value
Readmissions Measures Should Integrate Patient Experience, Community Health, Panel Says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
